Stocks and Investing
Stocks and Investing
Tue, November 8, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, November 7, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mani Foroohar Maintained (BEAM) at Buy with Decreased Target to $81 on, Nov 7th, 2022
Mani Foroohar of SVB Leerink, Maintained "Beam Therapeutics Inc." (BEAM) at Buy with Decreased Target from $82 to $81 on, Nov 7th, 2022.
Mani has made no other calls on BEAM in the last 4 months.
There are 2 other peers that have a rating on BEAM. Out of the 2 peers that are also analyzing BEAM, 1 agrees with Mani's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Maintained at Hold with Increased Target to $60 on, Wednesday, August 10th, 2022
This is the rating of the analyst that currently disagrees with Mani
- Rick Bienkowski of "SVB Leerink" Maintained at Buy with Decreased Target to $113 on, Wednesday, August 10th, 2022
Contributing Sources